Delayed emesis: Moderately emetogenic chemotherapy

Fausto Roila; David Warr; Rebecca A. Clark-Snow; Maurizio Tonato; Richard J. Gralla; Lawrence H. Einhorn; Jorn Herrstedt

doi:10.1007/s00520-004-0700-8

Delayed emesis: Moderately emetogenic chemotherapy

Fausto Roila, David Warr, Rebecca A. Clark-Snow, Maurizio Tonato, Richard J. Gralla, Lawrence H. Einhorn, Jorn Herrstedt

Research output: Contribution to journal › Review article › peer-review

64 Scopus citations

Abstract

Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT₃ antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.

Original language	English (US)
Pages (from-to)	104-108
Number of pages	5
Journal	Supportive Care in Cancer
Volume	13
Issue number	2
DOIs	https://doi.org/10.1007/s00520-004-0700-8
State	Published - Feb 2005
Externally published	Yes

Keywords

5-HT antagonist
Delayed emesis
Dexamethasone
Moderately emetogenic chemotherapy

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s00520-004-0700-8

Cite this

@article{0e7f9f04b88f4a33ad1944b6a37a9fe1,

title = "Delayed emesis: Moderately emetogenic chemotherapy",

abstract = "Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT3 antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.",

keywords = "5-HT antagonist, Delayed emesis, Dexamethasone, Moderately emetogenic chemotherapy",

author = "Fausto Roila and David Warr and Clark-Snow, {Rebecca A.} and Maurizio Tonato and Gralla, {Richard J.} and Einhorn, {Lawrence H.} and Jorn Herrstedt",

year = "2005",

month = feb,

doi = "10.1007/s00520-004-0700-8",

language = "English (US)",

volume = "13",

pages = "104--108",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Delayed emesis

T2 - Moderately emetogenic chemotherapy

AU - Roila, Fausto

AU - Warr, David

AU - Clark-Snow, Rebecca A.

AU - Tonato, Maurizio

AU - Gralla, Richard J.

AU - Einhorn, Lawrence H.

AU - Herrstedt, Jorn

PY - 2005/2

Y1 - 2005/2

N2 - Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT3 antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.

AB - Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT3 antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.

KW - 5-HT antagonist

KW - Delayed emesis

KW - Dexamethasone

KW - Moderately emetogenic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=17644396048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644396048&partnerID=8YFLogxK

U2 - 10.1007/s00520-004-0700-8

DO - 10.1007/s00520-004-0700-8

M3 - Review article

C2 - 15549426

AN - SCOPUS:17644396048

SN - 0941-4355

VL - 13

SP - 104

EP - 108

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 2

ER -

Delayed emesis: Moderately emetogenic chemotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this